At first glance, Ricky Brar might not look like your typical biotech CEO. He’s not a scientist in a lab coat or a boardroom lifer — he’s a farmer. Or at least, he was.
But that’s precisely what makes Brar, the founder and CEO of Brains Bioceutical Corp., one of the most compelling figures in the rapidly evolving world of plant-based pharmaceuticals. With deep roots in agriculture and a sharp eye for market shifts, Brar has taken a seed-to-farm herb business and turned it into one of the world’s leading cannabinoid-based biotech ventures.
Brains Bioceutical, under his leadership, is proving that the next billion-dollar biotech doesn’t have to come from Silicon Valley — it can come from the soil.
From Fields to Pharma
Brar’s journey began in the nutraceutical space, where he built a vertically integrated operation supplying herbs to major grocers and pharmaceutical companies across North America and Europe. At its peak, his farming operations stretched across 6,600 acres in eight countries. With an innate sense for consumer trends and regulatory readiness, Brar transitioned seamlessly into the cannabis industry long before it became mainstream.
In 2011, he co-founded Zenabis Global Inc., which grew to a CAD $900 million market cap and played a prominent role in shaping Canadian cannabis regulation. But Brar wasn’t finished. Where others saw cannabis as an endpoint, he saw a starting line for something much bigger — pharmaceutical-grade cannabinoids with global therapeutic potential.
A Global Biotech Built on Botanical Expertise
Brains Bioceutical is not just another cannabinoid company. Under Brar’s direction, it has become one of the only companies in the world to produce THC-free, EU-GMP certified CBD active pharmaceutical ingredients (APIs) at scale — a critical achievement for gaining traction in tightly regulated international markets.
Brains’ cannabinoid API is now part of over 30clinical trials and preclinical studies worldwide, including a Phase III clinical trial. The company has also achieved historic milestones, including becoming the first to register a medical cannabis product in Brazil and forging distribution partnerships with some of Europe’s most respected health and wellness brands.
Brar’s agricultural instincts remain central to the company’s strategy. “Whether it’s farming or pharmaceuticals, it’s all about consistency, compliance, and innovation,” he says. “We’ve taken the discipline of the field and applied it to the lab.”
Rewriting the Future of Medicine — One Plant at a Time
What makes Brains unique isn’t just its pharmaceutical focus — it’s the infrastructure and credibility behind it. The company operates under ICH-Q7 manufacturing standards, with active Drug Master Files filed in the U.S. and Europe, and rigorous testing that meets the requirements of Informed Choice, NSF, and WADA.
In an industry crowded with hype, Brains Bioceutical stands apart through execution. Its partnerships with legacy pharma companies and global vitamin distributors show that Brar’s team isn’t playing in the wellness aisle — they’re reshaping the future of pharmaceutical drugs.
Plant-Based, Science-Led, Future-Focused
As more countries modernize their approach to plant-based medicine, Brar sees Brains as a leader in a new class of pharmaceutical companies — one grounded in agriculture, powered by science, and unafraid to reimagine what’s possible with plants.
For a kid who started in the fields, Ricky Brar has come a long way. But even now, with Brains Bioceutical at the forefront of a global cannabinoid biotech wave, he hasn’t lost sight of his roots.
“The future of medicine,” Brar says, “might look a lot more like the past — just with better science.”
And the future for Brains? With its expanding drug portfolio, regulatory momentum, and growing footprint across Europe, North America, South America, and the Middle East, Brains Bioceutical is positioning itself to become a generational company — one that defines how plant-based therapeutics will be developed, trusted, and delivered around the world. The company isn’t just building better medicines — it’s building the blueprint for an entirely new industry. And at the heart of it all is a farmer who never stopped growing.
